Bremelanotide 1kits (10Vials)

Bremelanotide (PT-141 / Vyleesi) – Full Details & Benefits 1. Basic Introduction Bremelanotide (code name PT-141 , brand name Vyleesi® ) is a synthetic cyclic heptapeptide and a stabilized analog of α-MSH (alpha-melanocyte-stimulating hormone) . It is a melanocortin receptor agonist developed to regulate sexual desire and arousal via central nervous system pathways. Classification : Peptide / Melanocortin receptor agonist Molecular formula : C₅₀H₆₈N₁₄O₁₀ Appearance : White lyophilized powder (research grade) or sterile solution for injection Form : Subcutaneous injection (1.75 mg/0.3 mL auto-injector) Purity : ≥98% HPLC Key targets : MC1R, MC3R, MC4R (brain & skin) FDA approval : June 2019 (for premenopausal women with HSDD) 2. Mechanism of Action Bremelanotide binds to and activates melanocortin receptors (MCRs) in the brain (hypothalamus, limbic system) and skin: MC4R (primary) : Modulates sexual desire, arousal & motivation ; boosts dopaminergic pathways linked to sexual reward. MC3R : Regulates energy balance, mood & sexual responsiveness. MC1R : Stimulates melanin production → mild skin darkening (tan). Central (not vascular) action : Unlike ED drugs (e.g., sildenafil), it works via brain desire centers , not blood flow. 3. Main Benefits & Effects 1. Treats Female Hypoactive Sexual Desire Disorder (HSDD) FDA-approved indication : Acquired, generalized HSDD in premenopausal women (low desire causing distress). Clinical results : In Phase 3 trials, it increased sexual desire , reduced sexual distress , and improved satisfying sexual events vs. placebo. On-demand use : Injected 45 minutes before activity ; effects last ~8–12 hours. Non-hormonal : No estrogen/testosterone; safe for women avoiding hormone therapy. 2. Enhances Sexual Arousal & Satisfaction Boosts subjective arousal, sensitivity & orgasmic function in women with HSDD. Improves sexual motivation & responsiveness to stimuli. 3. Off-Label: Male Sexual Health (Research/Clinical Use) Erectile dysfunction (ED) : Improves erection quality & duration (especially with PDE5 inhibitors). Low libido : Increases sexual desire & drive in men. 4. Mild Skin Tanning (MC1R effect) Stimulates natural melanin → gradual, even bronze skin tone. Reduces sunburn risk; no UV exposure needed. 5. Appetite & Metabolic Support (Research) Modulates MC4R → mild appetite suppression & reduced cravings. May support body recomposition (fat loss, muscle preservation) in preclinical models. 6. Mood & Stress Regulation Activates limbic MCRs → mood lift, reduced anxiety & emotional balance . 4. Dosage & Administration (Research/Clinical) Standard dose : 1.75 mg subcutaneous injection (abdomen/thigh) 45–60 minutes before sexual activity. Frequency : Max 1 dose every 24 hours ; not daily long-term. Research form : Lyophilized powder reconstituted with bacteriostatic water (1–2 mg/mL). 5. Safety & Side Effects Common Mild (Transient) Flushing (face/neck warmth) Mild nausea (10–15% users) Headache (mild, short-lived) Injection site redness/itching Mild blood pressure spike (+2–4 mmHg, transient) Rare/Serious Severe hypertension (avoid in uncontrolled high BP) Allergic reaction (rare) Not for pregnant/nursing women Key Safety Notes No addiction potential No hormonal disruption Not for postmenopausal women or men (FDA-approved label) 6. Summary Bremelanotide (PT-141/Vyleesi) is a first-in-class melanocortin peptide that targets brain MC3R/MC4R to boost sexual desire & arousal —the only FDA-approved non-hormonal treatment for HSDD in premenopausal women . It also offers off-label benefits for male libido/ED , mild natural tanning , and appetite control . Its central mechanism (brain desire, not blood flow) makes it unique from other sexual health drugs.